RGX 104

Drug Profile

RGX 104

Alternative Names: RGX-104

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Rgenix
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Liver X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Glioblastoma; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 29 Oct 2017 Interim pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in solid tumours and lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 29 Oct 2017 Preliminary immunogenicity data from a phase Ia/b trial in solid tumours and lymphoma released by Rgenix
  • 01 Nov 2016 Phase-I clinical trials in Lymphoma (Late-stage disease) in USA (PO) (NCT02922764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top